Premier Medical Laboratory Services06.13.19
Premier Medical Laboratory Services, based in Greenville, S.C., is offering the first ever predictive test for type 2 diabetes, a test that is expected to mark a new era in diabetes prevention and care. The DIABETESpredict, developed by the European company Patia, and originally introduced in Europe and Mexico, evaluates whether a patient is at a high, medium, or low risk of suffering from type 2 diabetes by examining individual genetic profiles.
From a simple buccal swab or a blood sample, the DIABETESpredict determines the DNA sequence of sixteen single nucleotide polymorphisms in sixteen genes through a high-performance genotyping platform at Premier Medical Laboratory. Once that data is gathered, Patia’s proprietary mathematical algorithm offers a risk score. In addition, the DIABETESpredict results report provides individualized diet, exercise, and lifestyle recommendations informed by the genetic profile detected in each person.
“No two diabetics are the same, that’s why, after rigorous analysis, we offer customized lifestyle recommendations to make DIABETESpredict as effective as possible for each unique person,” stated Dr. Mirella Zulueta, medical director at Patia. “Patia has analyzed in detail the results of the largest scientific studies and meta-analyses of the human genome in diabetics. Altogether such studies collected information from more than 110,000 diabetic and non-diabetic people to identify the genetic variants most associated with type 2 diabetes.”
Of the world’s population, an estimated 500 million people suffer from type 2 diabetes today. The information provided by this test will help doctors anticipate monitoring routines and lifestyle interventions to prevent type 2 diabetes and create customized plans for newly diagnosed diabetics that could save their lives. This could have a profound effect on the world’s overall health. Gestational diabetes affects up to 14% of pregnancies worldwide, and those people who are at risk of diabetes are also more prone to cancer and cardiovascular disease.
Once the customized recommendations are created for each patient, DIABETESpredict also offers integrated wearable pedometers, smartphone, and web-based apps and games to aid these patients in their treatment plan and to help ensure that they stay on track.
“The wearable devices enable motivation, intervention, and monitoring of diet and physical exercise, as well as anthropometric, biochemical, and pharmaceutical follow-up,” commented Dr. Mirella Zulueta, medical director at Patia. “We also support patients with behavior change personal recommendations. The patient is our focus”.
DIABETESpredict is available in the U.S. through Premier Medical Laboratory Services. Family practitioners are encouraged to add this to their bloodwork during routine physicals. Weight management clinics and pediatricians can also benefit from the ability to know sooner and take advantage of the life-changing knowledge that DIABETESpredict provides.
From a simple buccal swab or a blood sample, the DIABETESpredict determines the DNA sequence of sixteen single nucleotide polymorphisms in sixteen genes through a high-performance genotyping platform at Premier Medical Laboratory. Once that data is gathered, Patia’s proprietary mathematical algorithm offers a risk score. In addition, the DIABETESpredict results report provides individualized diet, exercise, and lifestyle recommendations informed by the genetic profile detected in each person.
“No two diabetics are the same, that’s why, after rigorous analysis, we offer customized lifestyle recommendations to make DIABETESpredict as effective as possible for each unique person,” stated Dr. Mirella Zulueta, medical director at Patia. “Patia has analyzed in detail the results of the largest scientific studies and meta-analyses of the human genome in diabetics. Altogether such studies collected information from more than 110,000 diabetic and non-diabetic people to identify the genetic variants most associated with type 2 diabetes.”
Of the world’s population, an estimated 500 million people suffer from type 2 diabetes today. The information provided by this test will help doctors anticipate monitoring routines and lifestyle interventions to prevent type 2 diabetes and create customized plans for newly diagnosed diabetics that could save their lives. This could have a profound effect on the world’s overall health. Gestational diabetes affects up to 14% of pregnancies worldwide, and those people who are at risk of diabetes are also more prone to cancer and cardiovascular disease.
Once the customized recommendations are created for each patient, DIABETESpredict also offers integrated wearable pedometers, smartphone, and web-based apps and games to aid these patients in their treatment plan and to help ensure that they stay on track.
“The wearable devices enable motivation, intervention, and monitoring of diet and physical exercise, as well as anthropometric, biochemical, and pharmaceutical follow-up,” commented Dr. Mirella Zulueta, medical director at Patia. “We also support patients with behavior change personal recommendations. The patient is our focus”.
DIABETESpredict is available in the U.S. through Premier Medical Laboratory Services. Family practitioners are encouraged to add this to their bloodwork during routine physicals. Weight management clinics and pediatricians can also benefit from the ability to know sooner and take advantage of the life-changing knowledge that DIABETESpredict provides.
